{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:11:07Z","timestamp":1793085067055,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Studies which examine quality of life (QOL) provide important insights that are needed to understand the impacts of HIV\/AIDS anti-retroviral treatment (ART), comorbid conditions and other factors on the daily activities of people living with HIV\/AIDS (PLH). This study aimed to determine the inter-relationships between clinical factors, behavioural, socio-demographic variables and QOL among PLH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The secondary analysis used data collected from 293 people living with HIV\/AIDS (PLH) receiving second-line ART in Johannesburg in a clinical trial which evaluated the non-inferiority of ritonavir-boosted darunavir (DRV\/r 400\/100\u00a0mg) compared to ritonavir-boosted lopinavir (LPV\/r) over a 48\u00a0week-period. Physical functioning, cognitive and mental QOL were measured using the Aids Clinical Trial Group questionnaire. Exploratory factor analyses were used to examine the structure, the relationships between and the construct validity of QOL items. Structural equation models which tested the a priori-hypothesised inter-relationships between QOL and other variables were estimated and goodness of fit of the models to the data was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients on darunavir presented with lower pill burden. Older patients and women were more likely to report lower QOL scores. Pill burden mediated the effects of age, sex and treatment regimen on physical functioning QOL and adverse effects; the effects of age, sex, treatment regimen and adverse effects on cognitive QOL; and the effects of sex on mental QOL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>QOL among PLH is associated with socio-demographic and clinical factors. Therefore, QOL could be enhanced by considering PLH characteristics, clinical factors such as regimen side-effects profile, management of comorbid conditions and mitigating risks such as potential adverse drug-to-drug interactions among patients on ART.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-022-07429-9","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:04:40Z","timestamp":1652346280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa"],"prefix":"10.1186","volume":"22","author":[{"given":"Nomcebo Oratile","family":"Mokgethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Christofides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercilene","family":"Machisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godspower","family":"Akpomiemie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Lalla-Edward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"7429_CR1","unstructured":"WHO. Measuring quality of life. WHO-QOL. 1997. http:\/\/www.who.int\/mental_health\/media\/68.pdf. Accessed 21 May 2015."},{"key":"7429_CR2","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S239429","author":"G Mamo","year":"2020","unstructured":"Mamo G, Chelkeba L, Chanie T. Health-related quality of life among people living with human immunodeficiency virus on highly active antiretroviral therapy in Ethiopia: PROQOL-HIV based survey Tsegaye Melaku. Patient Relat Outcome Meas. 2020. https:\/\/doi.org\/10.2147\/PROM.S239429.","journal-title":"Patient Relat Outcome Meas"},{"issue":"8","key":"7429_CR3","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s10461-011-9928-8","volume":"15","author":"M Pereira","year":"2011","unstructured":"Pereira M, Canavarro MC. Gender and age differences in quality of life and the impact of psychopathological symptoms among HIV-infected patients. AIDS Behav. 2011;15(8):1857\u201369. https:\/\/doi.org\/10.1007\/s10461-011-9928-8.","journal-title":"AIDS Behav"},{"issue":"1","key":"7429_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874613601610010034","volume":"10","author":"ABM Kharsany","year":"2016","unstructured":"Kharsany ABM, Karim QA. HIV infection and AIDS in sub-Saharan Africa: current status, challenges and opportunities. Open AIDS J. 2016;10(1):34\u201348. https:\/\/doi.org\/10.2174\/1874613601610010034.","journal-title":"Open AIDS J"},{"issue":"6","key":"7429_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126810","volume":"10","author":"D Mutabazi-Mwesigire","year":"2015","unstructured":"Mutabazi-Mwesigire D, Katamba A, Martin F, Seeley J, Wu AW. Factors that affect quality of life among people living with HIV attending an urban clinic in Uganda: a cohort study. PLoS ONE. 2015;10(6): e0126810. https:\/\/doi.org\/10.1371\/journal.pone.0126810.","journal-title":"PLoS ONE"},{"issue":"3","key":"7429_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/2325957415599213","volume":"16","author":"BY Arjun","year":"2017","unstructured":"Arjun BY, Unnikrishnan B, Ramapuram JT, Thapar R, Mithra P, Kumar N, et al. Factors influencing quality of life among people living with HIV in coastal South India. J Int Assoc Provid AIDS Care. 2017;16(3):247\u201353. https:\/\/doi.org\/10.1177\/2325957415599213.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"1","key":"7429_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.antiviral.2009.10.007","volume":"85","author":"JA Est\u00e9","year":"2010","unstructured":"Est\u00e9 JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antivir Res. 2010;85(1):25\u201333. https:\/\/doi.org\/10.1016\/j.antiviral.2009.10.007.","journal-title":"Antivir Res"},{"issue":"4","key":"7429_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ajp.2011.10.006","volume":"4","author":"V Jagannath","year":"2011","unstructured":"Jagannath V, Unnikrishnan B, Hegde S, Ramapuram JT, Rao S, Achappa B, et al. Association of depression with social support and self-esteem among HIV positives. Asian J Psychiatry. 2011;4(4):288\u201392. https:\/\/doi.org\/10.1016\/j.ajp.2011.10.006.","journal-title":"Asian J Psychiatry"},{"issue":"3","key":"7429_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/09540120802241863","volume":"21","author":"F Bajunirwe","year":"2009","unstructured":"Bajunirwe F, Tisch DJ, King CH, Arts EJ, Debanne SM, Sethi AK. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. AIDS Care. 2009;21(3):271\u20139. https:\/\/doi.org\/10.1080\/09540120802241863.","journal-title":"AIDS Care"},{"issue":"7","key":"7429_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1080\/09540121.2016.1173639","volume":"28","author":"N Mafirakureva","year":"2016","unstructured":"Mafirakureva N, Dzingirai B, Postma MJ, Van HM, Khoza S. Health-related quality of life in HIV\/AIDS patients on antiretroviral therapy at a tertiary care facility in Zimbabwe. AIDS Care. 2016;28(7):904\u201312. https:\/\/doi.org\/10.1080\/09540121.2016.1173639.","journal-title":"AIDS Care"},{"issue":"1","key":"7429_CR11","doi-asserted-by":"publisher","first-page":"18643","DOI":"10.7448\/IAS.16.1.18643","volume":"16","author":"S Degroote","year":"2013","unstructured":"Degroote S, Vogelaers DP, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, et al. Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study. J Int AIDS Soc. 2013;16(1):18643. https:\/\/doi.org\/10.7448\/IAS.16.1.18643.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"7429_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/01.qai.0000186371.95301.52","volume":"41","author":"TR Glass","year":"2006","unstructured":"Glass TR, De GS, Weber R, Vernazza PL, Rickenbach M, Furrer H, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients the Swiss HIV cohort study. J AIDS. 2006;41(3):385\u201392. https:\/\/doi.org\/10.1097\/01.qai.0000186371.95301.52.","journal-title":"J AIDS"},{"key":"7429_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12877-018-0817-0","volume":"18","author":"M Ssonko","year":"2018","unstructured":"Ssonko M, Stanaway F, Mayanja HK, Namuleme T, Cumming R, Kyalimpa JL, et al. Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda. BMC Geriatr. 2018;18:125. https:\/\/doi.org\/10.1186\/s12877-018-0817-0.","journal-title":"BMC Geriatr"},{"issue":"12","key":"7429_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2017.1377610","volume":"10","author":"A Chary","year":"2017","unstructured":"Chary A, Nguyen NN, Maiton KHM. A review of drug-drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017;10(12):1329\u201352. https:\/\/doi.org\/10.1080\/17512433.2017.1377610.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"7429_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-7547-4-20","volume":"4","author":"SM Cleary","year":"2006","unstructured":"Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa\u2014a primary data analysis. Cost Eff Resour Alloc. 2006;4:1\u201314. https:\/\/doi.org\/10.1186\/1478-7547-4-20.","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"7429_CR16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1590\/0104-1169.3534.2508","volume":"22","author":"ACDO Silva","year":"2014","unstructured":"Silva ACDO, Reis RK, Nogueira JA, Gir E. Quality of life, clinical characteristics and treatment adherence of people living with HIV\/AIDS. Rev Lat Am Enfermagem. 2014;22(6):994\u20131000. https:\/\/doi.org\/10.1590\/0104-1169.3534.2508.","journal-title":"Rev Lat Am Enfermagem"},{"issue":"1","key":"7429_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pec.2006.10.002","volume":"66","author":"A Luszczynska","year":"2007","unstructured":"Luszczynska A, Sarkar Y, Knoll N. Received social support, self-efficacy, and finding benefits in disease as predictors of physical functioning and adherence to antiretroviral therapy. Patient Educ Couns. 2007;66(1):37\u201342. https:\/\/doi.org\/10.1016\/j.pec.2006.10.002.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"7429_CR18","doi-asserted-by":"publisher","first-page":"1441783","DOI":"10.1080\/16549716.2018.1441783","volume":"11","author":"KN Pokhrel","year":"2018","unstructured":"Pokhrel KN, Pokhrel KG, Neupane SR. Harmful alcohol drinking among HIV-positive people in Nepal\u202f: an overlooked threat to anti-retroviral therapy adherence and health-related quality of life threat to anti-retroviral therapy adherence and health-related quality of life. Glob Health Action. 2018;11(1):1441783. https:\/\/doi.org\/10.1080\/16549716.2018.1441783.","journal-title":"Glob Health Action"},{"issue":"8","key":"7429_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1089\/apc.2014.0076","volume":"28","author":"MA Levi-minzi","year":"2014","unstructured":"Levi-minzi MA, Surratt HL. HIV stigma among substance abusing people living with HIV\/AIDS: implications for HIV treatment. AIDS Patient Care STDS. 2014;28(8):442\u201351. https:\/\/doi.org\/10.1089\/apc.2014.0076.","journal-title":"AIDS Patient Care STDS"},{"key":"7429_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-94-007-6324-1","volume-title":"Stigma, discrimination and living with HIV\/AIDS","author":"VA Earnshaw","year":"2013","unstructured":"Earnshaw VA. Stigma, discrimination and living with HIV\/AIDS. Dordrecht: Springer; 2013. p. 23\u201338. https:\/\/doi.org\/10.1007\/978-94-007-6324-1."},{"issue":"1","key":"7429_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12889-018-5474-x","volume":"18","author":"DY Gebremichael","year":"2018","unstructured":"Gebremichael DY, Hadush KT, Kebede EM, Zegeye RT. Gender difference in health related quality of life and associated factors among people living with HIV\/AIDS attending anti-retroviral therapy at public health facilities, western Ethiopia: comparative cross sectional study. BMC Public Health. 2018;18(1):537. https:\/\/doi.org\/10.1186\/s12889-018-5474-x.","journal-title":"BMC Public Health"},{"key":"7429_CR22","unstructured":"Choi SW, Podrabsky T, Mckinney N, Schalet BD, Cook KF, Cella D, et al. Prosetta stone\u00ae analysis report a Rosetta stone for patient reported outcomes promis physical function and neuro-QOL mobility. http:\/\/www.prosettastone.org\/LinkingTables1\/Linking%20tables%20vol1\/PROMIS%20Physical%20Function%20and%20NeuroQOL%20Mobility%20Full%20Report.pdf. Accessed 22 May 2019."},{"issue":"11","key":"7429_CR23","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1097\/00002030-200307250-00012","volume":"17","author":"JR Marins","year":"2003","unstructured":"Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, Chequer P, Teixeira PRHN. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS. 2003;17(11):1675\u201382.","journal-title":"AIDS"},{"key":"7429_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jac\/dkm499","volume":"61","author":"RW Burgoyne","year":"2008","unstructured":"Burgoyne RW, Tan DHS. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother. 2008;61:469\u201373.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"7429_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/QAD.0000000000001738","volume":"32","author":"TS Torres","year":"2017","unstructured":"Torres TS, Harrison LJ, La RAM, Cardoso SW, Zheng L, Ngongondo M, et al. Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS. 2017;32(5):583\u201393.","journal-title":"AIDS"},{"issue":"14","key":"7429_CR26","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/QAD.0b013e32832e05b2","volume":"23","author":"O Keiser","year":"2009","unstructured":"Keiser O, Tweya H, Boulle A, Braitstein P, Schechter M, Brinkhof MWG, Dabis F, Tuboi S, Sprinz E, Pujades-Rodriguez M, Calmy A, Kumarasamy N, Nash D, Jahn A, Macphail P, L\u00fcthy R, Wood R, Egger M. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS. 2009;23(14):1867\u201374. https:\/\/doi.org\/10.1097\/QAD.0b013e32832e05b2.","journal-title":"AIDS"},{"key":"7429_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30081-5","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Serenata C, Akpomiemie G, Qavi A, et al. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019. https:\/\/doi.org\/10.1016\/S2352-3018(19)30081-5.","journal-title":"Lancet HIV"},{"key":"7429_CR28","unstructured":"Group ACT. Division of AIDS table for grading the severity of adult and pediatric adverse events. \u2026 Allergy Infect Dis Div AIDS. 2004;(August):1\u201321."},{"key":"7429_CR29","unstructured":"Wu AW. ACTG QOL 601\u2013602 health survey manual: adult AIDS Clin Trials Gr. 1998."},{"issue":"3","key":"7429_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/apc.2014.0255","volume":"29","author":"P Saberi","year":"2015","unstructured":"Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. AIDS Patient Care STDS. 2015;29(3):111\u20136. https:\/\/doi.org\/10.1089\/apc.2014.0255.","journal-title":"AIDS Patient Care STDS"},{"issue":"6","key":"7429_CR31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/(SICI)1099-1379(199711)18:6<667::AID-JOB874>3.0.CO;2-T","volume":"18","author":"AE Hurley","year":"1997","unstructured":"Hurley AE, Scandura TA, Schriesheim CA, Brannick MT, Seers A, Vandenberg RJ, et al. Exploratory and confirmatory factor analysis: guidelines, issues, and alternatives. J Organ Behav. 1997;18(6):667\u201383.","journal-title":"J Organ Behav"},{"key":"7429_CR32","series-title":"Pocket guides to social work","volume-title":"Confirmatory factor analysis","author":"D Harrington","year":"2009","unstructured":"Harrington D. Confirmatory factor analysis. Pocket guides to social work. Oxford: Oxford University Press; 2009."},{"issue":"2","key":"7429_CR33","first-page":"23","volume":"8","author":"K Schermelleh-Engel","year":"2003","unstructured":"Schermelleh-Engel K, Moosbrugger H, M\u00fcller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodnessof-fit measures. Methods Psychol Res Online. 2003;8(2):23\u201374.","journal-title":"Methods Psychol Res Online"},{"issue":"1","key":"7429_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"LT Hu","year":"1999","unstructured":"Hu LT, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6(1):1\u201355.","journal-title":"Struct Equ Model"},{"key":"7429_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/001316446002000116","volume":"20","author":"HF Kaiser","year":"1960","unstructured":"Kaiser HF. The application of electronic computers to factor analysis. Educ Psychol Meas. 1960;20:141\u201351.","journal-title":"Educ Psychol Meas"},{"issue":"2","key":"7429_CR36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1177\/1094428105285506","volume":"9","author":"RJ Vandenberg","year":"2006","unstructured":"Vandenberg RJ. Statistical and methodological myths and urban legends. Organ Res Methods. 2006;9(2):194\u2013201.","journal-title":"Organ Res Methods"},{"issue":"3","key":"7429_CR37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jmva.2009.09.014","volume":"101","author":"A B\u00fccher","year":"2010","unstructured":"B\u00fccher A, Dette H. Assessing model fit in structural equation modeling using appropriate test statistics. J Multivar Anal. 2010;101(3):749\u201363. https:\/\/doi.org\/10.1016\/j.jmva.2009.09.014.","journal-title":"J Multivar Anal"},{"issue":"7","key":"7429_CR38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40265-013-0040-4","volume":"73","author":"H Gakhar","year":"2013","unstructured":"Gakhar H, Kamali A, Holodniy M. Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs. 2013;73(7):651\u201372.","journal-title":"Drugs"},{"key":"7429_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.antiviral.2009.10.016","volume":"85","author":"T Hawkins","year":"2010","unstructured":"Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antivir Res. 2010;85:201\u20139.","journal-title":"Antivir Res"},{"key":"7429_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2012.04.010","volume":"95","author":"S Gupta","year":"2012","unstructured":"Gupta S, Knight AG, Losso BY, et al. Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance. Antivir Res. 2012;95:19\u201329.","journal-title":"Antivir Res"},{"key":"7429_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/HIV.S32321","volume":"4","author":"OO Oguntibeju","year":"2012","unstructured":"Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV\/AIDS Res Palliat Care. 2012;4:117\u201324.","journal-title":"HIV\/AIDS Res Palliat Care"},{"key":"7429_CR42","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/jac\/dkr248","volume":"66","author":"C Marzolini","year":"2011","unstructured":"Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, et al. Ageing with HIV: medication use and risk for potential drug\u2013drug interactions. J Antimicrob Chemother. 2011;66:2107\u201311.","journal-title":"J Antimicrob Chemother"},{"key":"7429_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3851\/IMP1540","volume":"15","author":"C Marzolini","year":"2010","unstructured":"Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Prevalence of comedications and effect of potential drug\u2013drug interactions in the Swiss HIV cohort study. Antivir Ther. 2010;15:413\u201323.","journal-title":"Antivir Ther"},{"issue":"13","key":"7429_CR44","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","volume":"23","author":"AM Mills","year":"2009","unstructured":"Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard P-M, et al. Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679\u201388.","journal-title":"AIDS"},{"issue":"9639","key":"7429_CR45","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","volume":"372","author":"J-M Molina","year":"2008","unstructured":"Molina J-M, et al. Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646\u201355.","journal-title":"Lancet"},{"issue":"1","key":"7429_CR46","first-page":"5","volume":"27","author":"AT Rodriguez-Penney","year":"2013","unstructured":"Rodriguez-Penney AT, Iudicello JE, Riggs PK, Doyle K, Ellis RJ, Letendre SL, et al. Co-morbidities in persons infected with HIV\u202f: increased burden with older age and negative effects on health-related quality of life. PLoS ONE. 2013;27(1):5\u201316.","journal-title":"PLoS ONE"},{"issue":"1","key":"7429_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2458-9-103","volume":"9","author":"E Wouters","year":"2009","unstructured":"Wouters E, Heunis C, van Rensburg D, Meulemans H. Physical and emotional health outcomes after 12 months of public-sector antiretroviral treatment in the Free State Province of South Africa: a longitudinal study using structural equation modelling. BMC Public Health. 2009;9(1):103. https:\/\/doi.org\/10.1186\/1471-2458-9-103.","journal-title":"BMC Public Health"},{"issue":"3","key":"7429_CR48","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/01.aids.0000390086.14941.91","volume":"24","author":"AM Bergenstrom","year":"2010","unstructured":"Bergenstrom AM, Abdul-Quader AS. Injection drug use, HIV and the current response in selected low-income and middle-income countries. AIDS. 2010;24(3):S20\u20139.","journal-title":"AIDS"},{"key":"7429_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1471-2458-9-98","volume":"9","author":"DC Thanh","year":"2009","unstructured":"Thanh DC, Moland KM, Fylkesnes K. The context of HIV risk behaviours among HIV-positive injection drug users in Viet Nam: moving toward effective harm reduction. BMC Public Health. 2009;9:98.","journal-title":"BMC Public Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07429-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07429-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07429-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:05:54Z","timestamp":1652346354000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07429-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7429"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07429-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The primary study was approved by the drug regulator (the South African Health Products Regulatory Authority), local research authority (Johannesburg Health District Research Committee), and the local institutional review board (University of the Witwatersrand Human Research Ethics Committee), and overseen by an independent data safety monitoring board (DSMB) (150705B). This trial is registered with ClinicalTrials.gov, number\n                      \n                      ; confirming that all experiments were performed in accordance with relevant South African regulatory guidelines and regulations. All participants provided written informed consent before the study. Ethical clearance was obtained from the University of the Witwatersrand Human Research Ethic Committee (Medical) for the secondary data analysis (M181001). All participants provided written informed consent before study commencement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"456"}}